Camporese Giuseppe, Bernardi Enrico, Noventa Franco
Unit of Angiology, Clinical Epidemiology Group, University Hospital of Padua, Italy.
Vasc Health Risk Manag. 2009;5:819-31. doi: 10.2147/vhrm.s3430. Epub 2009 Oct 12.
Parnaparin is a low-molecular-weight heparin that has widely shown its efficacy and safety in prevention of venous thromboembolism, in the treatment of chronic venous disorders, and in the treatment of venous and arterial (stable and unstable angina, acute ST-segment elevation myocardial infarction) thrombosis. Parnaparin at the respective dosages of 3200, 4250, 6400, or 12800 IUaXa for a period ranging from 3 to 5 days to 6 months, is usually administered subcutaneously by means of once-daily regimen and is better tolerated than unfractionated heparin at the injection site. In the variety of commercially available low-molecular-weight heparins, parnaparin represents a useful therapeutic option, even though little evidence is available comparing the superiority or the equivalent efficacy and safety of parnaparin to that of the unfractionated heparin or placebo. This review summarizes the available literature on the use of parnaparin in different settings of cardiovascular diseases, including papers published during the past year and ongoing studies.
帕肝素是一种低分子量肝素，已广泛显示出其在预防静脉血栓栓塞、治疗慢性静脉疾病以及治疗静脉和动脉（稳定型和不稳定型心绞痛、急性ST段抬高型心肌梗死）血栓形成方面的有效性和安全性。帕肝素以3200、4250、6400或12800 IUaXa的各自剂量给药3至5天至6个月，通常通过每日一次的方案皮下给药，并且在注射部位比普通肝素耐受性更好。在各种市售的低分子量肝素中，帕肝素是一种有用的治疗选择，尽管几乎没有证据可比较帕肝素与普通肝素或安慰剂相比的优越性或等效的有效性和安全性。本综述总结了关于帕肝素在不同心血管疾病环境中使用的现有文献，包括过去一年发表的论文和正在进行的研究。
